$2.18
+0.30 (+15.96%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NMTC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 observational
Held by 3 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 1.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for EpilepsyNCT07546253observationalEvaluate seizure outcomes | — | Not yet recruiting | Other: Participants are not assigned an intervention as part of the study. | Drug Resistant Epilepsy, Refractory Epilepsy | 100 | Jul 2028 | ≤ 711 d | 2026-04-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19